LivingGLP1
Study S003231

A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus

Registration

Registration
NCT03235219
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
TRIPLE
Status
COMPLETED
Enrollment
39
Start
2017-08-01
Primary completion
2018-02-19
Lead sponsor
Janssen Research & Development, LLC
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:JNJ-64565111; DRUG:Placebo
Results posted
FALSE
Secondary identifiers
OTHER:64565111EDI1002

Registered primary outcomes

  • Number of Participants With Adverse Events as a Measure of Safety and Tolerability [Up to Day 72]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.